Report cover image

Global Respiratory Virus Infection Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 195 Pages
SKU # APRC20356279

Description

Summary

According to APO Research, The global Respiratory Virus Infection Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Respiratory Virus Infection Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Respiratory Virus Infection Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Respiratory Virus Infection Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Respiratory Virus Infection Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Respiratory Virus Infection Drugs include Teva Pharmaceutical Industries Ltd., Sanofi, Merck and Co., Inc., GlaxoSmithKline plc, AstraZeneca, Orion Corporation, F. Hoffmann-La Roche Ltd., Cipla, Inc. and CHIESI Farmaceutici S.p.A., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Respiratory Virus Infection Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Respiratory Virus Infection Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Respiratory Virus Infection Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Respiratory Virus Infection Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Respiratory Virus Infection Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Respiratory Virus Infection Drugs sales, projected growth trends, production technology, application and end-user industry.

Respiratory Virus Infection Drugs Segment by Company

Teva Pharmaceutical Industries Ltd.
Sanofi
Merck and Co., Inc.
GlaxoSmithKline plc
AstraZeneca
Orion Corporation
F. Hoffmann-La Roche Ltd.
Cipla, Inc.
CHIESI Farmaceutici S.p.A.
Boehringer Ingelheim International GmbH
Respiratory Virus Infection Drugs Segment by Type

Nasal Decongestants
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Antibiotics
Cough Suppressants
Others
Respiratory Virus Infection Drugs Segment by Application

Retail Pharmacies
Drug Stores
Hospital Pharmacies
Clinics
Others
Respiratory Virus Infection Drugs Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Virus Infection Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Respiratory Virus Infection Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Virus Infection Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Respiratory Virus Infection Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Virus Infection Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Respiratory Virus Infection Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Respiratory Virus Infection Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Table of Contents

195 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Respiratory Virus Infection Drugs Market Size, 2020 VS 2024 VS 2031
1.3 Global Respiratory Virus Infection Drugs Market Size Estimates and Forecasts (2020-2031)
1.4 Global Respiratory Virus Infection Drugs Sales Estimates and Forecasts (2020-2031)
1.5 Global Respiratory Virus Infection Drugs Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Respiratory Virus Infection Drugs Market Dynamics
2.1 Respiratory Virus Infection Drugs Industry Trends
2.2 Respiratory Virus Infection Drugs Industry Drivers
2.3 Respiratory Virus Infection Drugs Industry Opportunities and Challenges
2.4 Respiratory Virus Infection Drugs Industry Restraints
3 Respiratory Virus Infection Drugs Market by Manufacturers
3.1 Global Respiratory Virus Infection Drugs Revenue by Manufacturers (2020-2025)
3.2 Global Respiratory Virus Infection Drugs Sales by Manufacturers (2020-2025)
3.3 Global Respiratory Virus Infection Drugs Average Sales Price by Manufacturers (2020-2025)
3.4 Global Respiratory Virus Infection Drugs Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Respiratory Virus Infection Drugs Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Respiratory Virus Infection Drugs Manufacturers, Product Type & Application
3.7 Global Respiratory Virus Infection Drugs Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Respiratory Virus Infection Drugs Market CR5 and HHI
3.8.2 Global Top 5 and 10 Respiratory Virus Infection Drugs Players Market Share by Revenue in 2024
3.8.3 2024 Respiratory Virus Infection Drugs Tier 1, Tier 2, and Tier 3
4 Respiratory Virus Infection Drugs Market by Type
4.1 Respiratory Virus Infection Drugs Type Introduction
4.1.1 Nasal Decongestants
4.1.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
4.1.3 Antibiotics
4.1.4 Cough Suppressants
4.1.5 Others
4.2 Global Respiratory Virus Infection Drugs Sales by Type
4.2.1 Global Respiratory Virus Infection Drugs Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Respiratory Virus Infection Drugs Sales by Type (2020-2031)
4.2.3 Global Respiratory Virus Infection Drugs Sales Market Share by Type (2020-2031)
4.3 Global Respiratory Virus Infection Drugs Revenue by Type
4.3.1 Global Respiratory Virus Infection Drugs Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Respiratory Virus Infection Drugs Revenue by Type (2020-2031)
4.3.3 Global Respiratory Virus Infection Drugs Revenue Market Share by Type (2020-2031)
5 Respiratory Virus Infection Drugs Market by Application
5.1 Respiratory Virus Infection Drugs Application Introduction
5.1.1 Retail Pharmacies
5.1.2 Drug Stores
5.1.3 Hospital Pharmacies
5.1.4 Clinics
5.1.5 Others
5.2 Global Respiratory Virus Infection Drugs Sales by Application
5.2.1 Global Respiratory Virus Infection Drugs Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Respiratory Virus Infection Drugs Sales by Application (2020-2031)
5.2.3 Global Respiratory Virus Infection Drugs Sales Market Share by Application (2020-2031)
5.3 Global Respiratory Virus Infection Drugs Revenue by Application
5.3.1 Global Respiratory Virus Infection Drugs Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Respiratory Virus Infection Drugs Revenue by Application (2020-2031)
5.3.3 Global Respiratory Virus Infection Drugs Revenue Market Share by Application (2020-2031)
6 Global Respiratory Virus Infection Drugs Sales by Region
6.1 Global Respiratory Virus Infection Drugs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Respiratory Virus Infection Drugs Sales by Region (2020-2031)
6.2.1 Global Respiratory Virus Infection Drugs Sales by Region (2020-2025)
6.2.2 Global Respiratory Virus Infection Drugs Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Respiratory Virus Infection Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Respiratory Virus Infection Drugs Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Respiratory Virus Infection Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Respiratory Virus Infection Drugs Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Respiratory Virus Infection Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Respiratory Virus Infection Drugs Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Respiratory Virus Infection Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Respiratory Virus Infection Drugs Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Respiratory Virus Infection Drugs Revenue by Region
7.1 Global Respiratory Virus Infection Drugs Revenue by Region
7.1.1 Global Respiratory Virus Infection Drugs Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Respiratory Virus Infection Drugs Revenue by Region (2020-2025)
7.1.3 Global Respiratory Virus Infection Drugs Revenue by Region (2026-2031)
7.1.4 Global Respiratory Virus Infection Drugs Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Respiratory Virus Infection Drugs Revenue (2020-2031)
7.2.2 North America Respiratory Virus Infection Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Respiratory Virus Infection Drugs Revenue (2020-2031)
7.3.2 Europe Respiratory Virus Infection Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Respiratory Virus Infection Drugs Revenue (2020-2031)
7.4.2 Asia-Pacific Respiratory Virus Infection Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Respiratory Virus Infection Drugs Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Respiratory Virus Infection Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Teva Pharmaceutical Industries Ltd.
8.1.1 Teva Pharmaceutical Industries Ltd. Comapny Information
8.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
8.1.3 Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Product Portfolio
8.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
8.2 Sanofi
8.2.1 Sanofi Comapny Information
8.2.2 Sanofi Business Overview
8.2.3 Sanofi Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Sanofi Respiratory Virus Infection Drugs Product Portfolio
8.2.5 Sanofi Recent Developments
8.3 Merck and Co., Inc.
8.3.1 Merck and Co., Inc. Comapny Information
8.3.2 Merck and Co., Inc. Business Overview
8.3.3 Merck and Co., Inc. Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Merck and Co., Inc. Respiratory Virus Infection Drugs Product Portfolio
8.3.5 Merck and Co., Inc. Recent Developments
8.4 GlaxoSmithKline plc
8.4.1 GlaxoSmithKline plc Comapny Information
8.4.2 GlaxoSmithKline plc Business Overview
8.4.3 GlaxoSmithKline plc Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 GlaxoSmithKline plc Respiratory Virus Infection Drugs Product Portfolio
8.4.5 GlaxoSmithKline plc Recent Developments
8.5 AstraZeneca
8.5.1 AstraZeneca Comapny Information
8.5.2 AstraZeneca Business Overview
8.5.3 AstraZeneca Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 AstraZeneca Respiratory Virus Infection Drugs Product Portfolio
8.5.5 AstraZeneca Recent Developments
8.6 Orion Corporation
8.6.1 Orion Corporation Comapny Information
8.6.2 Orion Corporation Business Overview
8.6.3 Orion Corporation Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Orion Corporation Respiratory Virus Infection Drugs Product Portfolio
8.6.5 Orion Corporation Recent Developments
8.7 F. Hoffmann-La Roche Ltd.
8.7.1 F. Hoffmann-La Roche Ltd. Comapny Information
8.7.2 F. Hoffmann-La Roche Ltd. Business Overview
8.7.3 F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Product Portfolio
8.7.5 F. Hoffmann-La Roche Ltd. Recent Developments
8.8 Cipla, Inc.
8.8.1 Cipla, Inc. Comapny Information
8.8.2 Cipla, Inc. Business Overview
8.8.3 Cipla, Inc. Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Cipla, Inc. Respiratory Virus Infection Drugs Product Portfolio
8.8.5 Cipla, Inc. Recent Developments
8.9 CHIESI Farmaceutici S.p.A.
8.9.1 CHIESI Farmaceutici S.p.A. Comapny Information
8.9.2 CHIESI Farmaceutici S.p.A. Business Overview
8.9.3 CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Product Portfolio
8.9.5 CHIESI Farmaceutici S.p.A. Recent Developments
8.10 Boehringer Ingelheim International GmbH
8.10.1 Boehringer Ingelheim International GmbH Comapny Information
8.10.2 Boehringer Ingelheim International GmbH Business Overview
8.10.3 Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Product Portfolio
8.10.5 Boehringer Ingelheim International GmbH Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Respiratory Virus Infection Drugs Value Chain Analysis
9.1.1 Respiratory Virus Infection Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Respiratory Virus Infection Drugs Production Mode & Process
9.2 Respiratory Virus Infection Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Respiratory Virus Infection Drugs Distributors
9.2.3 Respiratory Virus Infection Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.